Road to IPO in Hong Kong
About the Event
As the world's second largest funding hub for biotech, Hong Kong has unparalleled advantages for I&T in the biotech industry: internationally accredited support for drug certification which shortens the time into the Mainland market, acclaimed academia and research experts, comprehensive electronic medical data, and the one-stop support provided by HKSTP to see ideas from conception to commercialisation.
Since the pre-revenue biotech company listing regime took effect two years ago, HKEX has welcomed 16 pre-revenue biotech companies that have listed under Chapter 18A, raising a total of HK$39.7 billion. Alphamab Oncology, founded by former Boston pharmaceutical scientist Dr. Xu, was among one of them, raised $234 million and traded 35% higher from its offering price to a market cap of $1.2 billion.
With the new guidance materials for pre-revenue biotech companies recently published, this webinar aims to bring you the most updated information and relevant sharing from the key players of the ecosystem, and discuss how Hong Kong may be the place of choice to take a biotech company from startup to IPO.
How to become a SAPA-NE Member?
Paid Membership Rate
Student & Postdoc (Annual): $15
Professionals (Annual): $30
Note: Paid membership will be effective immediately after purchase.
- Ticket Pass$0$00$0